Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Alaunos Therapeutics, Inc. (TCRT)

0.4713   -0.001 (-0.23%) 03-24 16:00
Open: 0.4932 Pre. Close: 0.4724
High: 0.4932 Low: 0.4583
Volume: 338,577 Market Cap: 113(M)

Technical analysis

as of: 2023-03-24 4:30:24 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.68     One year: 0.78
Support: Support1: 0.45    Support2: 0.37
Resistance: Resistance1: 0.58    Resistance2: 0.67
Pivot: 0.51
Moving Average: MA(5): 0.47     MA(20): 0.52
MA(100): 0.71     MA(250): 1.05
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 14.1     %D(3): 15.4
RSI: RSI(14): 31.5
52-week: High: 4.01  Low: 0.4
Average Vol(K): 3-Month: 915 (K)  10-Days: 711 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TCRT ] has closed above bottom band by 26.8%. Bollinger Bands are 17.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.49 - 0.5 0.5 - 0.5
Low: 0.45 - 0.46 0.46 - 0.46
Close: 0.47 - 0.47 0.47 - 0.48

Company Description

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.

Headline News

Mon, 13 Mar 2023
Having purchased US$813k worth of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) stock, the recent 12% pullback is not what insiders may have expected - Simply Wall St

Fri, 10 Mar 2023
Q1 2023 EPS Estimates for Alaunos Therapeutics, Inc. Increased by ... - MarketBeat

Wed, 08 Mar 2023
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Q4 2022 Earnings Call Transcript - Yahoo Finance

Tue, 07 Mar 2023
Ziopharm: Q4 Earnings Snapshot - Danbury News Times

Tue, 07 Mar 2023
Ziopharm: Q4 Earnings Snapshot - Jacksonville Journal-Courier

Tue, 07 Mar 2023
Alaunos Therapeutics, Inc. Tops Q4 EPS by 1c By - Australia

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 241 (M)
% Held by Insiders 1.7717e+008 (%)
% Held by Institutions 8.9 (%)
Shares Short 24,090 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.998e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 120.4
Return on Equity (ttm) -25.7
Qtrly Rev. Growth 2.92e+006
Gross Profit (p.s.) 0
Sales Per Share -520.74
EBITDA (p.s.) 1.36667e+007
Qtrly Earnings Growth -0.2
Operating Cash Flow 0 (M)
Levered Free Cash Flow -29 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.44

Stock Dividends

Dividend 0
Forward Dividend 2.356e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.